Over all survival Time to treatment Failure | ||||||
---|---|---|---|---|---|---|
Stratification | Hazard ratio | p-value | 95% C.I. | Hazard ratio | p-value | 95% C.I. |
Sex (male/female) | 0.123 | 0.0128 | 0.024–0.640 | 0.225 | 0.0095 | 0.073–0.695 |
Age (≧69/<69) | 0.634 | 0.6082 | 0.111–3.692 | 2.380 | 0.2269 | 0.583–9.713 |
ECOG PS (PS0/PS1/PS2) | 0.016 | 0.0015 | 0.001–0.259 | 0.230 | 0.0007 | 0.001–0.152 |
Species of tumor (BDca/GBca) | 0.095 | 0.0198 | 0.013–0.688 | 0.001 | 0.0411 | 0.0856–0.943 |
Disease status (locally advanced/postoperative recurrence) | 0.121 | 0.0179 | 0.021–0.695 | 0.802 | 0.7388 | 0.001–0.152 |
Radiation (yes/no) | 8.369 | 0.1491 | 0.467–150.112 | 0.603 | 0.4586 | 0.158–2.299 |
Previous chemotherapy (yes/no) | 0.143 | 0.0255 | 0.016–1.241 | 0.495 | 0.4086 | 0.094–2.622 |
Initial CEA level (≧1 UL/<1 UL) | 1.098 | 0.9053 | 0.234–5.160 | 2.453 | 0.1267 | 0.775–7.763 |
Interval decreasing CEA level (yes/no) | 0.224 | 0.2859 | 0.014–3.499 | 1.734 | 0.5968 | 0.260–11.568 |
Initial CA19-9 level (≧5 UL/<5 UL) | 0.078 | 0.0255 | 0.014–3.499 | 1.734 | 0.5968 | 0.260–11.568 |
Interval decreasing CA19-9 level(yes/no) | 1.449 | 0.7667 | 0.125–16.774 | 0.326 | 0.2600 | 0.047–2.290 |